1. Capture
Isolate disease-relevant extracellular vesicles from blood, plasma, serum, or exosome-enriched samples without relying on magnetic bead workflows.
Vespera is building a liquid biopsy platform that captures and analyzes cancer-associated extracellular vesicles, starting with colorectal cancer and expanding toward pan-cancer detection and monitoring.
Detect | Understand | Transform
Current screening pathways can be invasive, episodic, or limited by compliance. A scalable blood-based test could help identify risk earlier, support clinical decision-making, and enable longitudinal monitoring across cancer types.
Isolate disease-relevant extracellular vesicles from blood, plasma, serum, or exosome-enriched samples without relying on magnetic bead workflows.
Read vesicle-associated signals with an optical and biomarker-driven assay designed for sensitivity, scalability, and clinical translation.
Begin with colorectal cancer as the wedge indication, then extend the platform to lung, pancreatic, breast, and broader pan-cancer applications.
Vespera is designed as a platform company, not a single-test project. The first clinical focus is colorectal cancer because it offers a clear unmet need, accessible clinical validation pathways, and a strong starting point for EV-based liquid biopsy development.
Co-founder · Computational Optics & AI
PhD Candidate, Electrical & Electronics EngineeringCo-founder · Biotechnology
Postdoctoral ResearcherStarting with colorectal cancer. Expanding toward all major cancers.
Contact the team